miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy.

Edyta Dziadkowiak Dagmara Baczyńska Małgorzata Wieczorek Mateusz Olbromski Helena MoreiraMonika MrozowskaSławomir BudrewiczPiotr DziegielEwa BargMagdalena Koszewicz

Published in: Oxidative medicine and cellular longevity (2023)

The results may support the hypothesis that miR-31-5p is strongly involved in the autoimmune process in CIDP. The positive correlation between higher miR-31-5p levels and duration of IVIg treatment may be an additional factor explaining the efficacy of prolonged IVIg therapy in CIDP.

Keyphrases

drug induced
positron emission tomography
risk assessment
computed tomography
pet imaging
human health
combination therapy
replacement therapy